Allos to Present at Needham and Company's Third Annual Biotechnology Conference

Allos to Present at Needham and Company's Third Annual
Biotechnology Conference 


WESTMINSTER, Colo., June 10  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) announced today that the company will participate in Needham and
Company's Third Annual Biotechnology Conference which is being held June 16-17
in New York City.  Michael E. Hart, President and Chief Executive Officer of
Allos will give a 35-minute presentation on June 16th at 1:30 p.m. ET.

The presentation will be webcast live and may be accessed by visiting the Allos
website at http://www.allos.com/.  A replay of the webcast will also be
available on the company's website until Wednesday, June 30, 2004.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor
tissues and enhance the efficacy of standard radiation therapy.  In addition,
Allos is developing PDX, a novel small molecule cytotoxic injectable antifolate
(DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma
and non-Hodgkin's lymphoma.  For more information, please visit the company's
web site at: http://www.allos.com/. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Fern Lazar of Lazar Partners, [phone] for Allos

Therapeutics, Inc.



Web site:  http://www.allos.com/ 

Copyright